Details for New Drug Application (NDA): 017535
✉ Email this page to a colleague
The generic ingredient in LORELCO is probucol. There are six drug master file entries for this compound. Additional details are available on the probucol profile page.
Summary for 017535
Tradename: | LORELCO |
Applicant: | Sanofi Aventis Us |
Ingredient: | probucol |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 017535
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
Approval Date: | Jul 6, 1988 | TE: | RLD: | No |
Expired US Patents for NDA 017535
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | LORELCO | probucol | TABLET;ORAL | 017535-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | LORELCO | probucol | TABLET;ORAL | 017535-002 | Jul 6, 1988 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | LORELCO | probucol | TABLET;ORAL | 017535-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription